Oncotarget

Research Papers:

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

Molly Gale, Joyce Sayegh, Jian Cao, Michael Norcia, Peter Gareiss, Denton Hoyer, Jane S. Merkel and Qin Yan _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:39931-39944. https://doi.org/10.18632/oncotarget.9539

Metrics: PDF 2098 views  |   HTML 1624 views  |   ?  


Abstract

Molly Gale1, Joyce Sayegh1,3, Jian Cao1, Michael Norcia2, Peter Gareiss2, Denton Hoyer2, Jane S. Merkel2, Qin Yan1

1Department of Pathology, Yale School of Medicine, New Haven, CT, USA

2Yale Center for Molecular Discovery, Yale University, West Haven, CT, USA

3Current address: Department of Biology and Chemistry, Azusa Pacific University, Azusa, CA, USA

Correspondence to:

Qin Yan, email: qin.yan@yale.edu

Keywords: histone demethylase inhibitor, KDM5A, anti-cancer drug, drug resistance, epigenetics

Received: February 23, 2016     Accepted: May 05, 2016     Published: May 21, 2016

ABSTRACT

Lysine demethylase 5A (KDM5A/RBP2/JARID1A) is a histone lysine demethylase that is overexpressed in several human cancers including lung, gastric, breast and liver cancers. It plays key roles in important cancer processes including tumorigenesis, metastasis, and drug tolerance, making it a potential cancer therapeutic target. Chemical tools to analyze KDM5A demethylase activity are extremely limited as available inhibitors are not specific for KDM5A. Here, we characterized KDM5A using a homogeneous luminescence-based assay and conducted a screen of about 9,000 small molecules for inhibitors. From this screen, we identified several 3-thio-1,2,4-triazole compounds that inhibited KDM5A with low μM in vitro IC50 values. Importantly, these compounds showed great specificity and did not inhibit its close homologue KDM5B (PLU1/JARID1B) or the related H3K27 demethylases KDM6A (UTX) and KDM6B (JMJD3). One compound, named YUKA1, was able to increase H3K4me3 levels in human cells and selectively inhibit the proliferation of cancer cells whose growth depends on KDM5A. As KDM5A was shown to mediate drug tolerance, we investigated the ability of YUKA1 to prevent drug tolerance in EGFR-mutant lung cancer cells treated with gefitinib and HER2+ breast cancer cells treated with trastuzumab. Remarkably, this compound hindered the emergence of drug-tolerant cells, highlighting the critical role of KDM5A demethylase activity in drug resistance. The small molecules presented here are excellent tool compounds for further study of KDM5A’s demethylase activity and its contributions to cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9539